Search - tctmd.com

Displaying 421 - 440 of 545

Sort: Relevancy | Date

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

August 01, 2017

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

News Daily News

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

July 24, 2017

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

News Daily News

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

Michael O'Riordan

July 11, 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

May 11, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

May 04, 2017

TCTMD’s Top 10 Most Popular Stories for April 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

April 28, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

One in Five Acute MI Patients Drop Statins Within 2 Years

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

If You Don’t Take Your Stroke Meds, This App Will Tell on You

News Daily News

If You Don’t Take Your Stroke Meds, This App Will Tell on You

April 18, 2017

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.